Johnson & Johnson MedTech right now introduced the promotion of Ahmet Tezel, Ph.D., to the place of Firm Group Chairman and International Head of MedTech Innovation and R&D.
Tezel will exchange Peter Shen, Ph.D., who will retire from the position on the finish of this 12 months after a J&J profession spanning greater than 25 years.
Tezel will be part of the Medtech international management crew and report back to J&J MedTech EVP and Worldwide Chair Ashley McEvoy because the unit focuses on making its services and products “smarter, much less invasive, and extra personalised,” the corporate mentioned in a information launch.
RELATED: Imagining the way forward for cloud-connected medical gadgets with Johnson & Johnson leaders
Tezel at present serves as worldwide VP of R&D for J&J Medtech’s Ethicon enterprise. Below his management, the Ethicon R&D pipeline worth elevated by greater than two-fold, the corporate mentioned.
“Ahmet additionally performed an integral position in creating synergies between Ethicon and the Robotics and Digital Options groups to reinforce integrations of expertise platforms and utilization of product growth finest practices,” the corporate mentioned. “Ahmet joined Johnson & Johnson with broad expertise within the medical expertise business together with a powerful historical past of driving innovation technique, delivering new merchandise to market in addition to retaining and advancing key expertise. He’s a Credo-based chief who is devoted to growing folks and creating an inclusive work atmosphere.”
Tezel beforehand held R&D management roles at Alcon and Allergan. He has a Ph.D. in chemical engineering from the College of California, Santa Barbara, in transdermal drug supply and vaccination, in addition to Bachelor of Science and Grasp of Science levels in chemical engineering from Bogazici College in Istanbul, Turkey.
Tezel and his household will proceed to stay in Summit, New Jersey.
New Brunswick, New Jersey-based J&J MedTech is the second-largest medical gadget producer on the planet, in response to Medical Design & Outsourcing‘s newest Medtech Huge 100 rating. The Johnson & Johnson (NYSE:JNJ) unit has about 75,000 staff and reported $27.1 billion in annual income for the fiscal 12 months ended Jan. 3, 2022.
RELATED: The ten largest medtech employers — and what their staff actually assume